Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0L9GG
|
|||
| Former ID |
DAP000239
|
|||
| Drug Name |
Alprazolam
|
|||
| Synonyms |
Alcelam; Algad; Alpaz; Alplax; Alpram; Alprax; Alprazolamum; Alprazolan; Alpronax; Alprox; Alviz; Alzam; Alzolam; Alzon;Anpress; ApoAlpraz; Azor; Bestrol; Cassadan; Constan; Esparon; Frontal; Helex; Intensol; Ksalol; Mialin; Neurol; Niravam; NovoAlprazol; NuAlpraz; Panistat; Panix; Pharnax; Prazam; Prazolan; Prinox; Ralozam; Relaxol; Restyl; Solanax; Tafil; Tensivan; Tranax; Trankimazin; Tranquinal; Tricalma; Unilan; Valeans; Xanagis; Xanax; Xanolam; Xanor; Zacetin; Zanapam; Zaxan; Zenax; Zolam; Zolan; Zolarem; Zoldac; Zoldax; Zopax; Zopic; Zotran; Alphapharm Brand of Alprazolam; Alprazolam Alphapharm Brand; Alprazolam Apotex Brand; Alprazolam Kenral Brand; Alprazolam Novopharm Brand; Alprazolam Orion Brand; Alprazolam Pfizer Brand; Alprazolam Temmler Brand; Alprazolam extended release tablets; Alprazolam intensol; Alprazolam solution; Apo Alpraz; Apotex Brand of Alprazolam; Arzneimittelwerk Dresden Brand of Alprazolam; Kenral Brand of Alprazolam; Novo Alprazol; Novopharm Brand of Alprazolam; Nu Alpraz; Nu Pharm Brand of Alprazolam; Orion Brand of Alprazolam; Pfizer Brand of Alprazolam; Tafil D; Temmler Brand of Alprazolam; Xanax TS; Xanax XR; D 65MT; D65MT; TGAR01P; Tus 1; U 31889; AP-1002; AZ-002; Alprazolam Nu-Pharm Brand; Alprazolam-d5; Alprazolamum [INN-Latin]; Apo-Alpraz; D-65MT; Gen-Alprazolan; Niravam (TN); Novo-Alprazol; Nu-Alpraz; Nu-Pharm Brand of Alprazolam; Staccato-alprazolam; TUS-1; U-31889; U31,889; Xanax (TN); Xanor (TN); U-31,889; Alprazolam (JP15/USP/INN); Alprazolam [USAN:INN:BAN:JAN]; 8-Chloro-1-methyl-6-(phenyl-d5)-4H-(1,2,4)triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-alpha)(1,4)benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Anxiety disorder [ICD-11: 6B00-6B0Z; ICD-10: R45.0] | Approved | [1], [2] | |
| Epilepsy [ICD-11: 8A60-8A68] | Phase 2 | [3] | ||
| Therapeutic Class |
Hypnotics and Sedatives
|
|||
| Company |
Pfizer Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H13ClN4
|
|||
| Canonical SMILES |
CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4
|
|||
| InChI |
1S/C17H13ClN4/c1-11-20-21-16-10-19-17(12-5-3-2-4-6-12)14-9-13(18)7-8-15(14)22(11)16/h2-9H,10H2,1H3
|
|||
| InChIKey |
VREFGVBLTWBCJP-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 28981-97-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9035, 866237, 7403853, 7847292, 7849651, 7978675, 8151436, 10517236, 12013413, 14742608, 14800856, 22396017, 24882050, 24891103, 24891366, 26719699, 29215419, 29215420, 29221298, 46386679, 46507078, 48415537, 50057265, 50823025, 53790970, 56313723, 57321151, 57651813, 57653873, 81093308, 92308240, 92716916, 93166633, 93167168, 93620403, 103189284, 103916140, 104299658, 109613253, 117786302, 124658860, 125347118, 126622623, 126651409, 126723170, 129515347, 131309066, 134221861, 134337553, 134997022
|
|||
| ChEBI ID |
CHEBI:2611
|
|||
| ADReCS Drug ID | BADD_D00085 | |||
| SuperDrug ATC ID |
N05BA12
|
|||
| SuperDrug CAS ID |
cas=028981977
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Translocator protein (TSPO) | Target Info | Agonist | [4], [5] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| HTLV-I infection | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7111). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 074046. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Comparison of five benzodiazepine-receptor agonists on buprenorphine-induced mu-opioid receptor regulation. J Pharmacol Sci. 2009 May;110(1):36-46. | |||
| REF 5 | Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.